NEW YORK (GenomeWeb News) - Rosetta Genomics today said it generated no first-quarter sales, while its R&D spending climbed 30 percent, and its net loss increased 33 percent year over year.
 
Rosetta, which went public in February, said that R&D spending for the three months ended March 31, 2007, increased to $1.16 million from $886,000 in the year-ago period. R&D accounted for 52 percent of the company’s spending during the quarter.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.